AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03571906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele - Cardiac Pre-Rehabilitation
Description: We intend to enroll 50 stable subjects with valvular heart disease scheduled for surgical intervention. Following a comprehensive clinical and physiological evaluation subjects will be randomized (1:1) to a Prehab arm (PHB) vs. usual care (UC). Subjects in the prehab arm will receive a hybrid institution and home-based exercise prescription, nutritional and psychological intervention and periodic calls. Adherence will be assessed and encouraged by smartwatch and matching smartphone software. In the usual care arm subjects will receive general recommendations following the baseline stress test performed by both groups (prehab is not standard of care or guideline based). Another stress test will be performed days prior to valve surgery Adherence to the rehab program will be assessed and a structured motivational program and follow-up will be provided in order to maximize goal completion.
Study NCT03442998 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Suburban walk
Description: Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
Study NCT03442998 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nature walk
Description: Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
Study NCT01688388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy
Description: Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
Study NCT03999294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMGIM Music Therapy Method
Description: The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
Study NCT02009332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
Study NCT02009332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is administered after ABI-009 in the Phase 2 study.
Study NCT02070276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-thoracic echocardiography
Description: Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
Study NCT02070276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Leg Raising Test
Description: Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
Study NCT02936609 — intervention group
Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
Study NCT01390753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human donor milk
Study NCT02912338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistant Training
Study NCT02912338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Study NCT01505309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent Graft (Medtronic, Microport, Ankura)
Description: Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
Study NCT01280721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
Study NCT02411175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Homeopathic Remedy
Description: 20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
Study NCT00521222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA
Description: Secondary as-needed rescue medication in all treatment groups
Study NCT00521222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol HFA
Description: Secondary as-needed rescue medication in all treatment groups
Study NCT00556413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT04295317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody SHR-1210
Description: PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
Study NCT04295317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
Study NCT01986166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
Study NCT01986166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
Study NCT00556413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00556413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00556413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00556413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT02163421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab injection, for subcutaneous use (vedolizumab SC)
Study NCT02163421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab IV
Description: Vedolizumab injection, for intravenous use (vedolizumab IV)
Study NCT04004013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lifenol®
Description: Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day
Study NCT04004013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day
Study NCT01415492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD2
Description: The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
Study NCT01415492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD2+
Description: The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
Study NCT02578329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensively advised Mediterranean diet
Description: Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
Study NCT01661062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography (CT) Scan
Description: Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
Study NCT01696760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 325 mg twice a day
Study NCT01222975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: orally disintegrating tablets
Study NCT01222975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: orally disintegrating tablets
Study NCT00987116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone - Azathioprine
Description: Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days.
Study NCT03261947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931
Description: TAK-931 hard gelatin capsules
Study NCT05938751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAm_YOUNG ADULTS program
Description: The TEAm_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
Study NCT03857984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: blood sample before and after a single HD
Study NCT02701647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
Study NCT02701647 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
Study NCT02701647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training
Description: Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
Study NCT02701647 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Treadmill training
Description: Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
Study NCT01696760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: 40 mg once daily
Study NCT01696760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCD
Description: Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
Study NCT00808314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT
Description: A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
Study NCT00808314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
Description: A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
Study NCT02404116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: Participants will receive treatment which focus's on helping reduce excessive thinking about health,
Study NCT02404116 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait List
Description: Individuals are on a waiting list
Study NCT01477723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Oral Nutritional Supplement
Description: Experimental ONS orally Two 8 fl oz servings/day
Study NCT01369979 — intervention group
Intervention type: PROCEDURE
Intervention: Liver vein catheter
Description: Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
Study NCT00778011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: dosage
Study NCT00778011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg
Study NCT00778011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg IV
Study NCT02168010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgecine
Description: Analgesic drug under test
Study NCT02168010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: Analgesic drug as positive control
Study NCT02168010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank tablet as placebo.
Study NCT05024500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARDSNet table
Description: The setting of the lowest PEEP level and FiO2 match stated by the table to achieve a goal oxygenation.
Study NCT05024500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving Pressure
Description: The setting of the lowest PEEP level by the lowest correspondent driving pressure, which is defined by the difference of plateau pressure, after a modified alveolar recruitment maneuver.
Study NCT05024500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: The setting of the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse, after a modified alveolar recruitment maneuver.
Study NCT00205426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrecor
Description: Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
Study NCT02447133 — intervention group
Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: OCT Machine used for diagnostic purposes
Study NCT04087460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein based pneumococcal vaccine(Low dose)
Description: 0.2mL,Intramuscular other name:PBPV
Study NCT04087460 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Protein based pneumococcal vaccine placebo(Low dose)
Description: 0.2mL,Intramuscular other name:PBPV placebo
Study NCT04087460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein based pneumococcal vaccine(Middle dose)
Description: 0.5mL,Intramuscular other name:PBPV
Study NCT04087460 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Protein based pneumococcal vaccine placebo(Middle dose)
Description: 0.5mL,Intramuscular other name:PBPV placebo
Study NCT04087460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein based pneumococcal vaccine(High dose)
Description: 1.0mL,Intramuscular other name:PBPV
Study NCT04087460 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Protein based pneumococcal vaccine placebo(High dose)
Description: 1.0mL,Intramuscular other name:PBPV placebo
Study NCT03632655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prostate biopsy
Description: Men will be randomized to receiving either TPM or TRUS targeted biopsy
Study NCT01787227 — intervention group
Intervention type: DEVICE
Intervention: xTAG RPP
Study NCT03657355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 will be administered as 50 mg tablets for oral use.
Study NCT03657355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.